These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22706491)

  • 1. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
    [No Abstract]   [Full Text] [Related]  

  • 2. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
    Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
    Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
    [No Abstract]   [Full Text] [Related]  

  • 4. Extramedullary involvement: an emerging problem in multiple myeloma.
    Molica S
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):268-9. PubMed ID: 22706492
    [No Abstract]   [Full Text] [Related]  

  • 5. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
    Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
    Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT; Rajkumar SV
    Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
    [No Abstract]   [Full Text] [Related]  

  • 7. [Bortezomib in second-line therapy].
    Musch A
    Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
    Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
    Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
    [No Abstract]   [Full Text] [Related]  

  • 9. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
    Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
    Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 12. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
    Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T
    Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in multiple myeloma.
    Vandenbroucke JP; Kroep JR
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
    [No Abstract]   [Full Text] [Related]  

  • 15. Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
    Pirrotta MT; Gozzetti A; Cerase A; Bucalossi A; Bocchia M; Defina M; Lauria F
    Onkologie; 2008 Feb; 31(1-2):45-7. PubMed ID: 18268398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
    Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
    [No Abstract]   [Full Text] [Related]  

  • 17. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
    Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib for myeloma -- much ado about something.
    Dispenzieri A
    N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
    [No Abstract]   [Full Text] [Related]  

  • 19. Concurrent radiation therapy and bortezomib in myeloma patient.
    Berges O; Decaudin D; Servois V; Kirova YM
    Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of intrapleural bortezomib in myelomatous pleural effusion.
    Iannitto E; Minardi V; Tripodo C
    Br J Haematol; 2007 Nov; 139(4):621-2. PubMed ID: 17979947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.